(Q34443398)

2 August 2017

1 reference

title

What in vitro models of infection can and cannot do. (English)

1 reference

2 August 2017

White RL

1

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

2 August 2017

1 reference

2 August 2017

volume

21

1 reference

2 August 2017

issue

11 Pt 2

1 reference

2 August 2017

page(s)

292S-301S

1 reference

Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Historical review of in-vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacokinetic considerations for the setting of in-vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

The bacteriolytic action of MT-141, a new cephamycin antibiotic, on gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Comparison Study of the Kinetics of Ceftizoxime Penetration into Extravascular Spaces with Known Surface Area/Volume Ratio In Vitro and In Vivo in Rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Correction for bacterial loss in in vitro dilution models

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

In vitro models for the study of combination antibiotic therapy in neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Quantitative analysis of antimicrobial effect kinetics in an in vitro dynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Model simulation of a single oral dose of cefuroxime axetil and the related in-vitro kill kinetics against four bacterial species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

In vitro evaluation of the determinants of bactericidal activity of ampicillin dosing regimens against Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Activity of amikacin against Mycobacterium avium complex under simulated in vivo conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Antibacterial kinetics of ampicillin against Escherichia coli under simulated in vivo conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Bactericidal Activity of Cephalosporins in an In Vitro Model Simulating Serum Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

The use of in vitro pharmacodynamic models of infection to optimize fluoroquinolone dosing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

In vivo verification of in vitro model of antibiotic treatment of device-related infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Comparison of in-vitro pharmacodynamics of once and twice daily ciprofloxacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear leucocyte chemokinesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

An in-vitro model simulating the hydrokinetic aspects of the treatment of bacterial cystitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Effect of protein binding on simulated intravascular and extravascular kinetics of cefotaxime in an in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Bactericidal activity of cefodizime on Enterobacteriaceae in an in-vitro model simulating plasma pharmacokinetics in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Bactericidal effect of amoxicillin on Helicobacter pylori in an in vitro model using epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Activity of imipenem in an in-vitro model simulating pharmacokinetic parameters in human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Application of in-vitro models: development of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Evaluation of the bactericidal activity of beta-lactam antibiotics on slowly growing bacteria cultured in the chemostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Artifacts in dilution pharmacokinetic models caused by adherent bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

In Vitro Model Simulating the Form of Exposure of Bacteria to Antimicrobial Drugs Encountered in Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Comparison of amoxicillin and ampicillin activities in a continuous culture model of the human urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Interface-area-to-volume ratio of interstitial fluid in humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Simultaneous simulation of two different concentration time curves in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Continuous infusion of beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Differences between in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Bacterial adhesion: modulation by antibiotics which perturb protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Adherence of Yersinia enterocolitica to mammalian epithelial cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Tests for bactericidal effects of antimicrobial agents: technical performance and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.18.292S.33906

10.1592/PHCO.21.18.292S.33906

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference